ShanXi C&Y Pharmaceutical Group Co.,Ltd. Stock: price and insider trades · China
仟源医药
No insider purchase over the last 90 days. The latest, by 黄乐群, was filed 10 Nov 2021.
ShanXi C&Y Pharmaceutical Group Co.,Ltd.: what insiders have been doing
ShanXi C&Y Pharmaceutical Group Co.,Ltd. belongs to the Health Care sector. Filings by its managers are published through SSE / SZSE (CSRC). ShanXi C&Y Pharmaceutical Group Co.,Ltd. has had no insider filing for more than a year; the last one goes back to 23 November 2021.
Over the whole record (from 2021), the tally stands at 2 purchases and 3 sales.
In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Since the insiders bought
- +19.6%Entry CN¥6.29 · Close at T+365 CN¥7.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 30,000 shares12.1% of flowA股XSHESZSE:173000005105592800
- 170,000 shares65.1% of flowA股XSHESZSE:173000005072387550
- 60,000 shares22.8% of flowA股XSHESZSE:173000005072387600
- 201,400 shares30.0% of flowA股XSHESZSE:173000005062441300Canonical exit: 8 Feb 2022 (T+90)
- 518,400 shares70.0% of flowA股XSHESZSE:173000005011564060Canonical exit: 25 Jan 2022 (T+90)
5 of 5 declarations
About ShanXi C&Y Pharmaceutical Group Co.,Ltd.
仟源医药 is a company specializing in the healthcare and pharmaceutical sector, providing a range of pharmaceutical products. It is listed on the XSHE market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
